People: Depomed Inc (DEPO.O)

DEPO.O on Nasdaq

15.58USD
11:06am EST
Price Change (% chg)

$0.32 (+2.12%)
Prev Close
$15.26
Open
$15.51
Day's High
$15.77
Day's Low
$15.36
Volume
241,219
Avg. Vol
--
52-wk High
--
52-wk Low
--

Search Stocks

Summary

Name Age Since Current Position

Peter Staple

62 2009 Independent Chairman of the Board

James Schoeneck

57 2011 President, Chief Executive Officer, Director

August Moretti

63 2012 Chief Financial Officer, Senior Vice President

Matthew Gosling

43 2011 Senior Vice President, General Counsel

Srinivas Rao

44 2014 Chief Medical Officer and Senior Vice President

R. Scott Shively

57 2014 Chief Commercial Officer, Senior Vice President

Richard Shively

2014 Senior Vice President, Chief Commercial Officer

Thadd Vargas

48 2008 Senior Vice President - Business Development

Steve Greco

64 2011 Vice President - Sales

Kevin Weber

56 2011 Vice President - Marketing

Jeff Coon

51 2011 Vice President - Human Resources

Gerd Kochendoerfer

46 2011 Vice President - Technical Development and Quality

Vicente Anido

51 2013 Independent Director

Karen Dawes

62 2008 Independent Director

Louis Lavigne

66 2013 Independent Director

Samuel Saks

59 2012 Independent Director

David Zenoff

76 2007 Independent Director

Biographies

Name Description

Peter Staple

Mr. Peter D. Staple serves as the Independent Chairman of the Board of Depomed Inc. He has served as a director of the Company since November 2003, and as Chairman of the Board since March 2009. Since March 2008, Mr. Staple has served as Chief Executive Officer and a director of Corium International, Inc., a privately-held biopharmaceutical company. From 2002 to March 2008 he served as director, and from 2002 to November 2007 as Chief Executive Officer, of BioSeek, Inc., a privately-held drug discovery company. From 1994 to 2002, Mr. Staple was a member of the senior executive team at ALZA Corporation, where he was most recently Executive Vice President, Chief Administrative Officer and General Counsel. Prior to joining ALZA, Mr. Staple held the position of Vice President, Associate General Counsel for Chiron Corporation, a biopharmaceutical company. Mr. Staple previously served as Vice President and Associate General Counsel for Cetus Corporation, a biotechnology company. Mr. Staple holds B.A. and J.D. degrees from Stanford University.

James Schoeneck

Mr. James A. Schoeneck serves as President, Chief Executive Officer, Director of Depomed Inc. He joined the Company as President and Chief Executive Officer in April 2011 and has served as a director of the Company since December 2007. From 2005 until joining the Company, Mr. Schoeneck was Chief Executive Officer of BrainCells Inc., a private biopharmaceutical company. Prior to joining BrainCells, he served as Chief Executive Officer of ActivX BioSciences, a development stage biotechnology company. Mr. Schoeneck's broad pharmaceutical experience also includes three years as President and Chief Executive Officer of Prometheus Laboratories Inc. Prior to joining Prometheus, Mr. Schoeneck spent three years at Centocor, Inc., where he led the development of Centocor's commercial capabilities. His group launched Remicade®, which has become one of the world's pharmaceutical products. Earlier in his career, he spent 13 years at Rhone-Poulenc Rorer, Inc. (now Sanofi) serving in various sales and marketing positions of increasing responsibility. Mr. Schoeneck currently serves as a director of FibroGen, Inc. Mr. Schoeneck holds a B.S. degree in Education from Jacksonville State University.

August Moretti

Mr. August J. Moretti serves as Chief Financial Officer, Senior Vice President of Depomed Inc., since January 2012. From 2004 to December 2011, Mr. Moretti served as Chief Financial Officer and Senior Vice President of Alexza Pharmaceuticals, Inc., a publicly held pharmaceutical company. From 2001 to 2004, Mr. Moretti served as Chief Financial Officer of Alavita, Inc. (formerly Surromed, Inc.), a privately held biotechnology company. Prior to Alavita, Mr. Moretti was a member of Heller Ehrman LLP, an international law firm. Mr. Moretti holds a J.D. from Harvard Law School and a B.A. degree in economics from Princeton University.

Matthew Gosling

Mr. Matthew M. Gosling is Senior Vice President, General Counsel of Depomed Inc., since January 2011. He served as Vice President and General Counsel since June 2006. Prior to joining the Company, Mr. Gosling was a member of Heller Ehrman LLP, an international law firm. Mr. Gosling holds a J.D. from the University of Chicago and a B.A. degree from Trinity University.

Srinivas Rao

Dr. Srinivas G. Rao M.D., Ph.D. is Chief Medical Officer and Senior Vice President of the Company. Dr. Rao has extensive experience and background in pain and central nervous system diseases. He was the Founder and Chief Executive Officer of Kyalin Biosciences, a privately held biotechnology company developing a potential breakthrough therapy for autism, from its formation in 2011 through to its sale to Retrophin, Inc in 2013. In 2014, he served as Executive Vice President and Head of Neuroscience at Retrophin. From 2011 to 2013, Dr. Rao also served as CMO and CSO of 3 companies through his association with Avalon Ventures. Finally, from 2001 to 2011, he was Chief Scientific Officer of Cypress Bioscience where he had a broad range of responsibilities, from business to clinical development. He was the innovator behind Savella™, postulating that this drug's unique pharmacology would be effective for fibromyalgia. Savella™ was approved by the FDA for this indication in 2009. Dr. Rao received his MD from Yale School of Medicine and his PhD in neurobiology from Yale Graduate School. Dr. Rao is a member of the American College of Neuropharmacology, the American Pain Society, International Association for the Study of Pain and the Society for Neuroscience.

R. Scott Shively

Mr. R. Scott Shively is Chief Commercial Officer, Senior Vice President of the Company. Mr. Shively has extensive commercial leadership experience in sales and marketing of pain and neurology products, for both specialty as well as larger pharmaceutical companies. Mr. Shively served as Executive Vice President and Chief Commercial Officer of Zogenix from November 2012 through August 2014 where he directed all commercial efforts of the company. From 2009 to 2012, he was Vice President - Global Commercial Disease Area Lead for Pain for Pfizer, Inc., where he had global commercial leadership responsibility for Pfizer's marketed pain products, including Lyrica and Celebrex, as well as for all pain pipeline products. From 2007 to 2009, Mr. Shively was Senior Vice President for Commercial Operations at Alpharma Pharmaceuticals, a specialty pharmaceutical company focused on pain management, where he led the expansion of their commercial organization and new product launches, tripling brand sales within two years. Prior to Alpharma, Mr. Shively served as Senior Vice President for Global Respiratory as well as interim President and Chief Executive Officer, USA at Altana AG. At Altana, Mr. Shively was responsible for the company's U.S. operations, including a sales force of over 500 representatives. Prior to Altana, Mr. Shively was VP of Marketing for Endo Pharmaceuticals for five years, during a period of rapid growth of Lidoderm and other pain and CNS brands. Earlier in his career, Mr. Shively held a variety of international and domestic commercial leadership roles at subsidiaries of Sanofi-Aventis. Mr. Shively received a B.S. in Zoology from Duke University with a pre-medical focus.

Richard Shively

Mr. Richard Scott Shively has been appointed as Senior Vice President and Chief Commercial Officer of the Company, effective September 2, 2014. Since November 2012, Mr. Shively has served as Chief Commercial Officer of Zogenix, Inc., a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. From October 2009 to November 2012, Mr. Shively served as Vice President, Global Commercial Disease Area Lead for pain at Pfizer Inc. From April 2007 to March 2009, Mr. Shively served as Senior Vice President for commercial operations at Alpharma Pharmaceuticals, Inc., a specialty pharmaceutical company focused on pain management. From September 2005 to March 2007, Mr. Shively served as Senior Vice President for Global Respiratory as well as interim President and Chief Executive Officer, USA at ALTANA AG. Earlier in his career, Mr. Shively served in a number of sales and marketing as well as international and domestic commercial leadership roles at subsidiaries of Sanofi-Aventis for nearly 20 years. Mr. Shively holds a B.S. from Duke University.

Thadd Vargas

Mr. Thadd M. Vargas is Senior Vice President - Business Development of DepoMed, Inc., since December 2008. He served as Vice President, Business Development since December 2002. Prior to joining the Company, Mr. Vargas served as Vice President of Finance at Worldres.com, Inc., Director of Finance at Kosan Biosciences, Inc. and Director of Business Development at Anergen, Inc. Prior to joining Anergen, Mr. Vargas was a member of Ernst & Young's life sciences audit practice. Mr. Vargas holds a B.A. degree in Business Economics from the University of California at Santa Barbara.

Steve Greco

Mr. Steve L. Greco is Vice President, Sales of Depomed Inc. He has served as Vice President, Sales since May 2011. From 2007 to 2011, Mr. Greco served as the Chief Business Officer of Marine Polymer Technologies, a privately-held medical device company that commercializes cardiovascular medical devices. From 2002 to 2007, Mr. Greco served as president of Publicis Selling Solutions, a pharmaceutical contract sales organization he founded in 2001. Prior to joining Publicis, Mr. Greco spent 14 years in sales management at Bristol-Myers Squibb, most recently as Senior Vice President, Cardiovascular/Metabolic Sales. Mr. Greco holds a B.A. from Loyola University of Los Angeles.

Kevin Weber

Mr. Kevin D. Weber is Vice President, Marketing of Depomed Inc. He has served as Vice President, Marketing since July 2011. From 2007 to 2011, Mr. Weber served as Senior Vice President, Global Operations and Strategy at Hyperion Therapeutics, Inc., a biopharmaceutical company focused on orphan diseases and President of BioMark Partners, a strategic marketing consulting firm. From 1999 to 2007, Mr. Weber was at Medicis Pharmaceutical Corporation, including as Vice President, Division Head of Ucyclyd Pharma Inc. Mr. Weber also spent 12 years serving in various marketing and product management roles at Rhone-Poulenc Rorer Inc. (now Sanofi). Mr. Weber holds a B.A. from Western Michigan University.

Jeff Coon

Mr. Jeff P. Coon is Vice President, Human Resources of Depomed, Inc. He has served as Vice President, Human Resources since September 2011. From 2009 to August 2011, Mr. Coon served as Human Resources Director at Cobham plc. From 2008 to 2009, Mr. Coon served as the Vice President of Human Resources of Exelixis, Inc. From 2006 to 2008, Mr. Coon served as the Executive Director of Human Resources at PDL BioPharma Inc. Prior to joining PDL BioPharma, Mr. Coon served as Vice President Human Resources at CD Holding and Human Resources Director at Johnson and Johnson. Mr. Coon holds a B.A. from California State University Long Beach and a M.S. in Human Resources Management from Golden Gate University in San Francisco.

Gerd Kochendoerfer

Dr. Gerd G. Kochendoerfer is Vice President, Technical Development and Quality. Dr. Kochendoerfer has served as Vice President, Technical Development and Quality since 2011 after having served since 2008 as Senior Director, Project Management. From 2005 to January 2008, Dr. Kochendoerfer served as Senior Director, Drug Development at FibroGen, Inc., a privately-held biotechnology company. Prior to joining FibroGen, Dr. Kochendoerfer, served as Director of Research and Development of Gryphon Therapeutics, Inc. Dr. Kochendoerfer holds a Ph.D. in chemistry from the University of California at Berkeley.

Vicente Anido

Dr. Vicente Anido, Jr., Ph.D., has been Independent Director of Depomed, Inc., since February 2013. Dr. Anido is the former President, Chief Executive Officer and Director of Ista Pharmaceuticals, Inc., which was acquired by Bausch + Lomb Incorporated in 2012. Prior to joining Ista Pharmaceuticals, Dr. Anido served as general partner of Windamere Venture Partners from 2000 to 2001. From 1996 to 1999, Dr. Anido served as President and Chief Executive Officer of CombiChem, Inc., a drug discovery company. From 1993 to 1996, Dr. Anido served as President of the Americas Region of Allergan, Inc., where he was responsible for Allergan's commercial operations for North and South America. Prior to joining Allergan, Dr. Anido spent 17 years at Marion Laboratories and Marion Merrell Dow, Inc., including as Vice President, Business Management of Marion's U.S. Prescription Products Division. Dr. Anido holds a B.S. and a M.S. from West Virginia University and a Ph.D. from the University of Missouri, Kansas City.

Karen Dawes

Ms. Karen A. Dawes is Independent Director of Depomed, Inc., since April 2008. Since 2003, Ms. Dawes has served as President of Knowledgeable Decisions, LLC, a pharmaceutical consulting firm that she founded. Between 1999 and 2003, Ms. Dawes served as Senior Vice President and U.S. Business Group Head for Bayer Corporation's U.S. Pharmaceuticals Group. Prior to joining Bayer, she served as Senior Vice President, Global Strategic Marketing for Wyeth, formerly known as American Home Products, where she held responsibility for worldwide strategic marketing. She also served as Vice President, Commercial Operations for Genetics Institute, Inc., which was acquired by Wyeth in 1997. Ms. Dawes began her pharmaceutical industry career at Pfizer, Inc. where, from 1984 to 1994, she held a number of positions in Marketing, serving most recently as Vice President, Marketing of the Pratt Division. Ms. Dawes currently serves as a director of Repligen Corporation and several private companies. Ms. Dawes holds an M.B.A. from Harvard University, and B.A. and M.A. degrees from Simmons College.

Louis Lavigne

Mr. Louis J. Lavigne, Jr., is Independent Director of Depomed, Inc., effective July 6, 2013. Mr. Lavigne currently serves as Managing Director of Lavrite, LLC, a management consulting firm specializing in the areas of corporate finance, accounting, growth strategy and management. Mr. Lavigne served as Executive Vice President and Chief Financial Officer of Genentech, Inc. from 1997 through his retirement in 2005. Mr. Lavigne joined Genentech in 1982 and assumed the position of Chief Financial Officer in 1988 and was named Senior Vice President in 1994. Mr. Lavigne was a member of Genentech's Executive Committee, Chairman of its 401K Plan Committee, and responsible for its Financial, Corporate Relations and Information Technology groups. The Board considered Mr. Lavigne's experience and expertise within the following areas relevant to the Company and its business in concluding that he should serve on the Board: Corporate Finance; Commercial Strategy; Commercial Operations; Strategic Transactions; Business Planning; and Board experience. Mr. Lavigne currently serves on the boards of directors of Allergan, Inc., Accurary Incorporated, DocuSign, Inc., Novocure Limited and SafeNet Inc. He is also Chairman of the Board of Children's Hospital, Oakland. Mr. Lavigne is a member of Deloitte's Life Sciences Advisory Board. Mr. Lavigne holds a B.A. from Babson College and a M.B.A. from Temple University.

Samuel Saks

Dr. Samuel R. Saks, M.D., has been Independent Director of Depomed, Inc., since October 2012. From April 2011 until February 2012, Dr. Saks served as interim Chief Medical Officer of Threshold Pharmaceuticals, Inc. From 2003 to 2009, Dr. Saks served as CEO of Jazz Pharmaceuticals, Inc., a specialty pharmaceutical company he co-founded. Prior to joining Jazz Pharmaceuticals, Dr. Saks held a number of positions at ALZA Corporation, which was acquired by Johnson & Johnson in 2001. From 2001 to 2003, he was Company Group Chairman of ALZA and served as a member of Johnson & Johnson's Pharmaceutical Group Operating Committee. From 1992 to 2001, he held various executive positions at ALZA, including Senior Vice President, Medical Affairs and Group Vice President, where he was responsible for clinical and commercial activities. He has also held clinical research positions in oncology at Schering-Plough Corporation, XOMA Corporation and Genentech, Inc. From 1987 to 2000, Dr. Saks was Assistant Clinical Professor of Medicine in the oncology division of the Department of Medicine at the University of California, San Francisco. Dr. Saks currently serves as a director of TONIX Pharmaceuticals, Inc. and several private companies. Dr. Saks received a B.S. and an M.D. from the University of Illinois.

David Zenoff

Dr. David B. Zenoff, D.B.A., serves as Independent Director of Depomed, Inc., since March 2007. Since 1973, Dr. Zenoff has been the President of David B. Zenoff and Associates, Inc., a strategy and management consulting firm. Dr. Zenoff has taught at various universities, including Stanford University Graduate School of Business, Columbia Graduate School of Business, and IMEDE in Lausanne, Switzerland. The Board considered Dr. Zenoff's experience and expertise within the following areas relevant to the Company and its business in concluding that he should serve on the Board: Corporate Strategy; Pharmaceutical Marketing Strategy; Organization Development; Management Practices; Board Processes and Governance; Strategic Transactions; and Corporate Leadership. Dr. Zenoff was a member of the board of directors of Williams-Sonoma for six years and currently serves as a director of ExamWorks Group, Inc. Dr. Zenoff holds a B.A. from Stanford University and M.B.A. and D.B.A. degree from Harvard University.

Options Compensation

Search Stocks